TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Is Vitamin D Insufficiency and Deficiency Associated With Antepartum and Postpartum Depression?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Evaluation at Roosevelt Hospital (Receiving prenatal care with St Luke's Roosevelt Hospital center private physicians and clinic) by 20w0d gestation.~* Planned delivery at Roosevelt Hospital Labor \& Delivery~* English or Spanish speaking~Exclusion Criteria:~* Non-english or non-spanish speaking~* Currently on anti-depressants/mood stabilizing medications~* Medical comorbidities affecting vitamin D absorption or metabolism:Bone disease (osteoporosis, osteomalacia); Malabsorption disorders (cystic fibrosis, inflammatory bowel disease, roux-en-y bariatric surgery); Chronic kidney disease; Severe liver disease; Granuloma forming disorders (active tuberculosis, sarcoidosis);Parathyroid disease; Lymphoma; HIV on HAART medication; anti-seizure medications.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vitamin D3 (cholecalciferol) treatment (Type: ACTIVE_COMPARATOR): 50,000 IU vitamin D3 (cholecalciferol) tablet weekly x 8 weeks plus prenatal vitamin (400 IU vitamin D)
- Vitamin D placebo (Type: PLACEBO_COMPARATOR): Placebo tablet (appearance same as active vitamin D) plus prenatal vitamin (400IU vitamin D)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Trial Evaluating Ambulatory Treatment of Travelers' Diarrhea

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Active duty military or military beneficiary, 18 years-old or older.~2. Presence of acute diarrhea (3 or more stools in 24 hours or 2 or more stools in 24 hours and associated symptoms such as nausea, vomiting, abdominal cramps or tenesmus) and \<96 hours duration.~3. Eligible for ambulatory management.~4. Able to comply with follow-up procedures.~5. Will remain in country for at least 7 days~Exclusion Criteria:~1. Allergy to rifamycins, quinolones, macrolides, or loperamide (not including mild gastrointestinal upset).~2. Antibiotic therapy in the 72 hours prior to presentation (excluding malaria prophylaxis with mefloquine, malarone, chloroquine/proguanil, or doxycycline).~3. Concomitant medications with known drug-drug interactions with any of the study drugs (includes theophylline, digoxin, and warfarin).~4. History of seizures (relative contraindication to quinolones)~5. Positive pregnancy test at presentation (contraindicated with fluoroquinolone therapy). All female subjects will be administered a urine pregnancy test prior to enrollment.~6. Presence of symptoms \>96 hours prior to initiating treatment.~7. Use of \>4 mg loperamide or use of any amount of loperamide for greater than 24 hours prior to enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Acute Watery Diarrhea (Type: EXPERIMENTAL): None
- Acute Dysentery/Febrile (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Mindfulness-Based Exercise Video in Educating Hispanic/Latino Patients With Colorectal Cancer and Their Caregivers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient diagnosed with colorectal cancer~* Patients with at least one more chemotherapy appointment at the time of enrollment~* if patients have a caregiver, patients should agree to bring a caregiver to one of their hospital visits or have the caregiver schedule a separate study visit~* Ability to understand and the willingness to sign a written informed consent~Exclusion Criteria:~* Illiterate participants~* Deaf participants~* Participants that do not read speak or understand either Spanish or English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group I (standard of care) (Type: NO_INTERVENTION): Patients and caregivers receive standard of care.
- Group II (educational video) (Type: EXPERIMENTAL): Patients and caregivers receive a 20-minute self-playing interactive educational video brochure.
- Group III (educational video, mindfulness exercise video) (Type: EXPERIMENTAL): Patients and caregivers receive a 20-minute self-playing interactive educational video brochure and watch a 20-minute interactive mindfulness exercise video.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Does Dietary and Lifestyle Counseling Prevent Excessive Weight Gain During Pregnancy? A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Establish prenatal care at 6 - 16 weeks gestation~2. 18-49 years of age~3. Receive their entire prenatal care at the Resident Obstetrics Clinic~4. English and/or Spanish speaking~5. Singleton gestation.~Exclusion Criteria:~1. Establish prenatal care \>16 weeks gestation~2. Non-English or non-Spanish speaking~3. Multiple gestation pregnancy~4. BMI \> 40~5. Preexisting diabetes, untreated thyroid disease, or hypertension requiring medication or other medical conditions that might affect body weight~6. Delivery at institution other than CMC-Main~7. Pregnancy ending in a premature delivery (\< 37 weeks)~8. Limited prenatal care (\<4 visits)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Intensive Counseling Group (Type: EXPERIMENTAL): None
- Routine care group (Type: NO_INTERVENTION): The routine care group took part in an initial physical exam and history, routine labs, and routine visits per American College of Obstetrics \& Gynecology (ACOG) standards. The only counseling on diet and exercise during pregnancy was that included in our standard prenatal booklet What to do When You're Having a Baby by Gloria Mayer (Institute for Health Advancement, 2003, La Habra, CA). At each routine obstetric appointment, the participant's weight was measured recorded in the medical chart. The healthcare provider did not counsel the participant regarding any changes in diet or lifestyle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Forearm Shaft Fractures: Plating of Radius and Ulna Versus Plating of Radius and Nailing of Ulna

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diaphyseal fractures of both radius and ulna~* Ulna fractures that are oblique or transverse~* Fractures may be closed or Grade I-IIIA open~* Patients must be over 18 and skeletally mature~Exclusion Criteria:~* Children under the age of 18~* Pregnancy~* Comminuted ulna fractures~* Those with associated bony elbow or wrist trauma~* Elbow dislocation~* Subjects with bone pathology (osteoporosis, OI, Paget's disease, bone cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- intramedullary nailing and plating (Type: ACTIVE_COMPARATOR): intramedullary nailing of the ulna and plating of the radius in the treatment of both bone forearm fractures
- plating (Type: ACTIVE_COMPARATOR): plating of both the radius and ulna in the treatment of both bone forearm fractures

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation Perioperative Nutrition on Donor Site Healing in Patients Undergoing Reconstructive Burn Surg

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least one year post-acute burn injury~* Admitted for surgery whereby split thickness donor site created~* Received initial acute treatment at Shriner's Hospital in Cincinnati~Exclusion Criteria:~* Less than 6years of age~* Less than one year from acute burn injury~* Split thickness donor site/autograft not anticipated~* Initial treatment not at Shriners Hospital in Cincinnati

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 24 Years
- Healthy Volunteers: t

Study Arms:
- A, treated (Type: EXPERIMENTAL): treated with Juven po supplement x 3 weeks postop
- B, control (Type: NO_INTERVENTION): Usual nutrition therapy received postop

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completion of Study B5201002.~* Documented diagnosis of SCD.~* At least 6 years of age.~* Male and female subjects of childbearing potential and at risk for pregnancy must agree to use a highly effective method of contraception throughout the study.~* Diagnosis of VOC necessitating IV opioids and admission to the hospital.~* Able to receive the first dose of rivipansel within 24 hours from administration of the first dose of IV opioids for this hospitalization.~Exclusion Criteria:~* Non-compliance with study procedures in the double blind study (B5201002).~* Occurrence of any severe and/or generalized cutaneous manifestation or any other adverse event during participation in Study B5201002 that was related to study drug and which would therefore make it inappropriate for the subject to receive rivipansel in the current study.~* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results.~* Clinically significant deterioration in renal function in Study B5201002.~* Pregnant female subjects, breastfeeding female subjects and male and female subjects of childbearing potential who are unwilling or unable to use a highly effective method of contraception.~* Active use of illicit drugs and/or alcohol dependence.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Includes one adult stratum (\>18 years old) and one pediatric stratum (12-17 years old). Subjects aged 12 and over who weigh \>40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg.
- Cohort 2 (Type: EXPERIMENTAL): Includes one pediatric stratum (6-11 years old). Subjects 6 to 11 years of age or subjects who weigh 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Advanced Reperfusion Strategies for Refractory Cardiac Arrest

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (presumed or known to be aged 18-75 years, inclusive),~* An initial documented OHCA rhythm of VF/VT,~* No ROSC following 3 defibrillation shocks,~* Body morphology able to accommodate a Lund University Cardiac Arrest System (LUCAS™) automated CPR device, and~* Estimated transfer time from the scene to the ED or CCL of \< 30 minutes.~Exclusion Criteria:~* Age \< 18 years old or \> 75 years old;~* Non-shockable initial OHCA rhythm (pulseless electrical activity \[PEA\] or asystole);~* Valid do-not-attempt-resuscitation orders (DNAR);~* Blunt, penetrating, or burn-related injury, drowning, electrocution or known overdose;~* Known prisoners;~* Known pregnancy;~* Nursing home residents;~* Unavailability of the cardiac catheterization laboratory.~* Severe concomitant illness that drastically shortens life expectancy or increases risk of the procedure;~* Absolute contraindications to emergent coronary angiography including known anaphylactic reaction to angiographic contrast media and/or active gastrointestinal or internal bleeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ECMO Facilitated Resuscitation (Type: EXPERIMENTAL): Regardless of whether return of spontaneous circulation (ROSC) has been achieved and with on-going mechanical CPR, patients will enter the Cardiac Catheterization Laboratory (CCL) for expeditious VAECMO initiation, if required, followed by coronary angiography and percutaneous coronary intervention (PCI) when appropriate.
- Standard ACLS Resuscitation (Type: OTHER): Patients with refractory VF/VT OHCA will be treated with ACLS resuscitation for at least 15 minutes after arrival in the emergency department (ED), or up to 60 minutes from 911 call, after which the physician (MD) can continue resuscitation efforts until ROSC is achieved or futility has been reached based on their clinical judgment. If the patient has not achieved ROSC during the times mentioned above, the ED MD can declare death when he or she believes that ACLS is futile. If ROSC is present upon arrival or has been achieved anytime during resuscitation in the ED, the patient will be taken to the cardiac catheterization laboratory (CCL) for coronary angiography and PCI, and potential VA ECMO or other circulatory support device initiation, as clinically indicated.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Advanced Head and Neck Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically and cytologically confirmed diagnosis of squamous cell carcinoma.~* Patients not amenable to curative treatments with further surgery and/or radiation.~* Patient has failed treatment with chemotherapy~* Lesions must be distinct and the minimum measurements must be at least 2.0 cm x 2.0 cm at baseline.~* Karnofsky performance rating of at lest 50%.~Exclusion Criteria:~* Patients with severe and unstable cardiovascular disease.~* Treatment naive subjects will not be included for study.~* Patients with poorly controlled diabetes, seizure disorder, primary CNS tumors or known brain metastases will be excluded.~* Pregnant or nursing women.~* Patients requiring antibiotics in the preceding 2 weeks for a serious infection are not eligible.~* Patients with a fever \> 37.8 degrees C.~* Pulse \< 60 or \> 110~* Systolic blood pressure \> 170 or less than 90 are not eligible.~* Patients with nasopharyngeal squamous cell carcinoma will be excluded~* Patients with hypercalcemia will be excluded from this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single Arm (Type: EXPERIMENTAL): Opioid Growth Factor (OGF)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Kidney Damage In Patients With Severe Fall In eGFR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Provides written Informed Consent~* Is at least 18 years of age;~* Is scheduled for or likely to undergo percutaneous coronary intervention;~* Has documented estimated glomerular filtration rate \[eGFR\] \< 30 mL/min/1.73 m2 calculated with the MDRD formula within 72 hours prior the enrolment.~Exclusion Criteria:~* Is a pregnant or lactating female~* Has a history of severe congestive heart failure~* Has a history of hyperthyroidism~* Has unstable renal function~* Has a history of hypersensitivity to iodinated contrast agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IOPAMIDOL injection 370 (Type: ACTIVE_COMPARATOR): None
- Iodixanol 320 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Self-adhering Mesh and Conventional Mesh in Inguinal Hernia Repair.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male~* Primary, unilateral inguinal hernia~* Age ≥18 years~* Social status: professionally employed~* ASA-score I-III~* Signed informed consent~* Elective surgery~Exclusion Criteria:~* Female~* Bilateral and/or recurrent inguinal hernia~* Femoral or scrotal hernia~* Vasectomy~* Social status: unemployed~* Chronic use of pain medication~* Symptomatic acute hernia (i.e. bowel obstruction, incarceration, strangulation, peritonitis or perforation of bowel contents)~* ASA-score IV or above~* Incapacitated adult or no signed informed consent~* Patient is unable to speak Dutch

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental - Cousin Biotech Adhesix (Type: EXPERIMENTAL): Placement of a self-adhering (sutureless) surgical mesh in open anterior inguinal hernia repair
- Conventional - Cousin Biotech Biomesh P8 (Type: ACTIVE_COMPARATOR): Placement of the conventional (sutured) surgical mesh in open anterior inguinal hernia repair

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study of Biomarker During Liver Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* liver resection \> 2 segments,~* plate count \> 100 x 109/L, and~* prothrombin activity \>60%.~Exclusion Criteria:~* liver cirrhosis,~* portal hypertension,~* steatohepatitis or severe steatosis,~* patients receiving additional ablation therapies,~* laparoscopic resection, and~* simultaneous extrahepatic procedures such as colorectal resection or pancreatoduodenectomy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Hepatocellular carcinoma (Type: None): Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Renin-Angiotensin System in Essential Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Essential Hypertension~* SBP 140-159 mmHg~* DBP 90-99 mmHg~Exclusion Criteria:~* Intolerance of or allergy to ACE Inhibitors or ARBS~* Pregnant or Breastfeeding~* Pre-menopausal women~* Uncontrolled cardiac or renal failure~* Diabetes mellitus

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Clipped Versus Handsewn Arteriovenous Fistula Anastomosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older.~* Need for AVF creation for vascular access for planned hemodialysis (within 1 year).~* The planned AVF site must be naïve of prior AVF creations.~* Vein mapping studies completed~* 2.5 - 3mm minimum vein diameter on mapping~Exclusion Criteria:~* Less than 18 years of age.~* Inability to provide consent.~* Previous failed AVFs in both arms.~* Contraindications to AVF creation:~  * ipsilateral proximal venous and arterial occlusion or stenosis~ * systemic or local infection~ * too ill to operate~* Anticipated inability to keep 30-day postoperative follow-up appointment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clipped anastomosis (Type: EXPERIMENTAL): A vascular clip device will be used to create the anastomosis during arteriovenous fistula creation.
- Handsewn anastomosis (Type: ACTIVE_COMPARATOR): A handsewn technique will be used to create the anastomosis in arteriovenous fistula creation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues